glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Dr. Dan on Retatrutide vs Ozempic: Obesity Expert Fact Check

Part of YouTube & Expert Fact Checks.

Dr. Dan on Retatrutide vs Ozempic: Obesity Expert Fact Check

Dr. Dan, a pharmacist and host of the Dr. Dan | Obesity Expert YouTube channel, breaks down retatrutide as the next-generation weight loss drug compared to existing GLP-1 medications. He walks through Saxenda, Wegovy, and Zepbound weight loss data before diving into retatrutide's Phase 2 trial results, the triple agonist mechanism, side effects including cardiac arrhythmia, and timeline predictions.

This page fact-checks his claims against the published clinical trial data.

Existing Drug Weight Loss Comparison

Dr. Dan sets up the progression of GLP-1 medications by comparing weight loss percentages: Saxenda at ~8%, Wegovy at ~15%, and Zepbound at ~21% from baseline.

ClaimPublished DataVerdict
Saxenda: ~8% weight loss from baselineSCALE Obesity trial (Pi-Sunyer et al., NEJM 2015): Liraglutide 3.0 mg achieved 8.0% mean weight loss at 56 weeks vs 2.6% placebo.Accurate
Wegovy: almost 15% weight loss from baselineSTEP 1 trial (Wilding et al., NEJM 2021): Semaglutide 2.4 mg achieved 14.9% mean weight loss at 68 weeks vs 2.4% placebo.Accurate
Zepbound: almost 21% weight loss from baselineSURMOUNT-1 trial (Jastreboff et al., NEJM 2022): Tirzepatide 15 mg achieved 20.9% at 72 weeks under the treatment-regimen estimand and 22.5% under the efficacy estimand. The ~21% figure matches the highest-dose treatment-regimen result.Approximately accurate

These are results from separate trials with different populations and analysis methods. They support the figures he quotes, but cannot isolate the effect of adding a receptor or predict which medicine will work best for an individual.

For a detailed comparison, see Retatrutide vs Zepbound and Retatrutide vs Wegovy.

The Triple Agonist Mechanism

Dr. Dan explains that retatrutide mimics three hormones — GLP-1, GIP, and glucagon — earning it the nickname "Triple G molecule." He correctly notes that glucagon has traditionally been understood as a counter-regulatory hormone to insulin, but has additional metabolic roles relevant to weight management.

ClaimPublished DataVerdict
Retatrutide is a triple hormone receptor agonist (GLP-1 + GIP + glucagon)Jastreboff et al., NEJM 2023: Retatrutide is described as a "triple-hormone-receptor agonist" activating GIP, GLP-1, and glucagon (GCG) receptors.Accurate
Glucagon is a counter-regulatory hormone to insulinThis is textbook physiology. Glucagon raises blood glucose when levels are low, opposing insulin's glucose-lowering effect.Accurate
Glucagon may have a role in metabolism beyond blood sugarPreclinical studies support effects on energy expenditure and hepatic lipid metabolism. Human retatrutide trials do not isolate how much weight loss each receptor contributes.Accurate
Dr. Dan's explanation of the triple agonist mechanism is solid. He wisely avoids oversimplifying glucagon's role and acknowledges the complexity is not yet fully understood. For a deeper dive, see How Retatrutide Works and What Is Retatrutide?.

Phase 2 Trial: Weight Loss Results

Dr. Dan reviews the Phase 2 trial design: approximately 340 individuals with obesity or overweight, split into about seven dose groups plus placebo, followed for 48 weeks.

ClaimPublished DataVerdict
~340 individuals enrolledJastreboff et al., NEJM 2023: 338 adults without diabetes were enrolled.Accurate
Split into about seven different groups plus placeboThe trial randomized participants into 7 arms: placebo plus 6 retatrutide dose groups (1 mg, 4 mg from 2 mg start, 4 mg from 4 mg start, 8 mg from 2 mg start, 8 mg from 4 mg start, 12 mg from 2 mg start).Approximate: seven arms in total, including placebo
Followed for 48 weeksTreatment period was 48 weeks.Accurate

Dr. Dan presents the dose-response data, highlighting that even the lowest dose (1 mg) produced meaningful weight loss, while the highest dose (12 mg) approached 25% — and the weight loss curves had not plateaued.

ClaimPublished DataVerdict
1 mg dose: ~9% weight loss from baselineNEJM 2023: 1 mg group achieved -8.7% at 48 weeks.Approximately accurate
12 mg dose: nearly 25% weight loss from baselineNEJM 2023: 12 mg group achieved -24.2% at 48 weeks (from 2 mg start). There was no 12 mg group starting at 4 mg.Approximately accurate
Weight loss had not plateaued at 48 weeksThe NEJM paper explicitly states participants had not reached a weight-loss plateau. TRIUMPH-4 later reported 28.7% at 68 weeks in a separate population with obesity or overweight and knee osteoarthritis; it was not an extension of Phase 2.Accurate

The 1 mg and 12 mg figures match the published efficacy analysis. A curve still declining at 48 weeks does not establish how much additional weight a person will lose or whether tolerability will allow continued treatment.

For the complete data, see Retatrutide Results.

The 100% Responder Rate

Dr. Dan highlights what he calls an almost unheard-of result: 100% of participants in the 8 mg and 12 mg groups lost at least 5% of their baseline weight. He estimates approximately 130 individuals across those groups.

ClaimPublished DataVerdict
100% of 8 mg and 12 mg groups lost ≥5% of baseline weightNEJM 2023: The efficacy-estimand percentages in the combined 8 mg and 12 mg groups were 100% for ≥5% weight loss. Additionally, 91-93% achieved ≥10% and 75-83% achieved ≥15%.Accurate
~130 individuals in the 8 mg and 12 mg groups combinedThe published allocation was 70 participants in the combined 8 mg groups and 62 in the 12 mg group: 132 randomized participants. Responder estimates are not a count of everyone originally randomized.Approximately accurate count

The 100% result describes the trial’s efficacy analysis at 48 weeks. It is not a guarantee that every person prescribed retatrutide would respond, and it should not be compared with another trial’s percentage without checking how discontinuations and missing data were handled.

Retatrutide Side Effects and the Cardiac Arrhythmia Question

Dr. Dan covers the side effect profile, noting the typical gastrointestinal effects (nausea, heartburn, constipation, diarrhea) and the absence of alarming signals like cancer, gastroparesis, or mental health issues. He then flags the cardiac arrhythmia finding as a "yellow flag."
ClaimPublished DataVerdict
No increased risk of cancers, gastroparesis, or mental health issuesA 338-person, 48-week trial cannot exclude uncommon or long-term harms. One acute pancreatitis event occurred in a retatrutide participant. TRIUMPH-4 also reported dysesthesia, so its safety findings were not limited to GI effects.Not established
Typical GI side effects comparable to Wegovy and ZepboundNEJM 2023: The most common adverse events were GI — nausea, diarrhea, vomiting, constipation — consistent with the GLP-1 class.Accurate
5.6% experienced cardiac arrhythmiaThe Phase 2 adverse-event table reports cardiac arrhythmia events by randomized group, including placebo. It does not report 5.6% as a pooled retatrutide-only incidence. A pooled percentage must not silently include placebo participants.Denominator needs qualification
Heart rate increased with higher doses but came back down over timeThe Phase 2 data showed dose-dependent heart rate increases, particularly in the first 12-24 weeks, with subsequent stabilization. The trial does not establish which receptor caused the change.Accurate
GLP-1 medications increase heart rate but provide cardiovascular benefitSELECT showed a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity without diabetes. That result does not establish retatrutide cardiovascular benefit.Accurate
The arrhythmia finding deserves follow-up, but “yellow flag” is his interpretation. Heart-rate changes alone cannot establish net cardiovascular benefit or harm. Retatrutide-specific outcomes evidence is needed; see Retatrutide Side Effects.

Too Much Weight Loss?

Dr. Dan raises the concern that some participants may have lost "too much weight," with BMI potentially dropping into the underweight category. He uses this to argue for a broader narrative shift around muscle preservation, nutrition, and goal-setting beyond the number on the scale.

ClaimPublished DataVerdict
Concern that continued weight loss could eventually become excessiveThe concern is conditional in his discussion. The Phase 2 publication does not show that participants reached underweight BMI; it should not be used to turn a hypothetical concern into an observed trial result.Overstated
Concern about losing too much muscle massA valid concern, but the published retatrutide body-composition substudy involved adults with type 2 diabetes at 36 weeks, not the 48-week obesity trial discussed here. Lean mass and skeletal muscle are not interchangeable.Valid concern
Nutrition, activity and changes in strength matter alongside total weight. Underweight BMI was not established as an outcome in this Phase 2 publication, and a diabetes body-composition substudy should not be presented as a finding from the obesity trial. See Retatrutide and Muscle Loss.

Timeline Predictions

Dr. Dan predicts that Phase 3 trials will wrap up around 2026 and that retatrutide probably won't be available on the market until late 2026 into 2027.

ClaimPublished DataVerdict
Phase 3 trials wrapping up around 2026Several pivotal obesity studies reported results in 2026, but head-to-head and cardiovascular-outcomes studies continue. The whole Phase 3 program has not wrapped up.Accurate
Market availability late 2026 into 2027Lilly now plans a US biologics license application in Q1 2027. No approval or launch date has been established.Prediction, not confirmed availability
Lilly reported TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 results in 2026 and plans a US biologics license application in the first quarter of 2027. Submission is not approval, and there is no established commercial launch date. Other Phase 3 studies continue. See Retatrutide Availability.

Frequently Asked Questions

Who is Dr. Dan the Obesity Expert?

Dr. Dan is a pharmacist with a Doctor of Pharmacy degree who runs the YouTube channel Dr. Dan | Obesity Expert. He creates educational content about obesity medications including GLP-1 receptor agonists, weight management strategies, and clinical trial data. He approaches the topic from a clinical perspective and encourages viewers to consult with their own healthcare providers.

Is retatrutide better than Ozempic for weight loss?

Retatrutide has produced larger average reductions in separate obesity trials, but that does not prove superiority to Ozempic for an individual. Ozempic is a diabetes brand; Wegovy is the semaglutide obesity brand. Retatrutide remains investigational, and there is no completed direct trial against semaglutide establishing the comparison. See GLP-1 vs GLP-3 for the terminology.

What are the side effects of retatrutide?

Common trial events include nausea, diarrhea, vomiting and constipation. Heart-rate increases and altered skin sensation have also been reported. One acute pancreatitis event occurred in Phase 2; short trials cannot rule out rare harms. See Retatrutide Side Effects.

Does retatrutide cause heart problems?

Phase 2 reported dose-dependent heart-rate increases that peaked at 24 weeks and later declined, as well as cardiac arrhythmia events. These findings do not establish long-term cardiovascular benefit or harm. Results from approved GLP-1 medicines cannot be assumed to apply to retatrutide.

When will retatrutide be available?

Lilly reported TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 results in 2026 and plans a US biologics license application in the first quarter of 2027. Submission is not approval, and there is no established commercial launch date. Other Phase 3 studies continue.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Related reading

Retatrutide Results and Review: The Weight Loss Data by Dose
Explainer

Retatrutide Results and Review: The Weight Loss Data by Dose

Dose-by-dose trial results, with timepoints, analysis differences and limits on predicting individual weight loss.

Retatrutide Side Effects & Safety Data (2026)
Safety

Retatrutide Side Effects & Safety Data (2026)

Separate trial tables for retatrutide GI effects and dysesthesia, with rare-event findings and current safety uncertainties.

Retatrutide vs Zepbound: What's the Difference?
Comparison

Retatrutide vs Zepbound: What's the Difference?

Zepbound is an approved tirzepatide treatment. Retatrutide remains investigational; separate trial results do not prove a treatment advantage.

Retatrutide vs Wegovy: Triple Agonist vs GLP-1
Comparison

Retatrutide vs Wegovy: Triple Agonist vs GLP-1

Wegovy is approved in oral and injectable forms, including Wegovy HD. Retatrutide remains investigational with no completed direct comparison.

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker
Tracker

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker

Trial results with population, endpoint, duration and source context. Use the trial finder for recruitment.

Keep exploring

Explore all fact checks topics →